Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) drug for type II diabetes Miletus that plays an important role in lowering hemoglobin A1c, but its sub-cutaneous administration has caused a loss in its therapeutic efficacy. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.